Home » Topics » BioWorld Science, Hematologic

BioWorld Science, Hematologic
RSS

BT-200: prolonging half-life of vWF

June 15, 2021

Preliminary phase I results reported for OMS-906

June 10, 2021

FDA lifts clinical hold on studies of LentiGlobin in sickle cell disease and beta-thalassemia

June 8, 2021

SPK-10000, a liver-targeted gene therapy for the treatment of hereditary angioedema

June 1, 2021

Phase I trial explores use of BIVV-001 in adults with type 2N and 3 von Willebrand disease

May 31, 2021

FXIa inhibitor BMS-986177 well tolerated in patients with renal impairment

May 25, 2021

Phase I data on SLN-124 support ongoing evaluation in patients with thalassemia and MDS

May 19, 2021

Anti-BAFF therapy eradicates factor VIII inhibitors in hemophilia A

May 19, 2021

First patient dosed in phase I/II MAA-202 study of MarzAA

May 19, 2021

FDA approves Empaveli for PNH

May 17, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...